J&J says IMAAVY shows sustained disease control through two years in adolescent myasthenia gravis study

Bitget2026/09/29 12:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Johnson & Johnson announced new long-term data on IMAAVY for generalized myasthenia gravis, scheduled for presentation at AANEM 2026.
A Phase 2/3 adolescent extension study showed disease control and functional improvement held up through two years, with some steroid reduction.
A retrospective survey of adult treatment switches found inconsistent symptom control was the top reason to stop prior advanced therapy.
Clinicians reported most patients improved after moving to IMAAVY, with many also cutting prednisone use.
IMAAVY is positioned as an FcRn blocker with pediatric authorization in the U.S. and Europe for certain antibody-positive gMG patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609290803PR_NEWS_USPR_____NY58035) on September 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

J&J says IMAAVY shows sustained disease control through two years in adolescent myasthenia gravis study

You may also like

Crypto prices